Literature DB >> 6690259

Steroid receptors in pulmonary lymphangiomyomatosis.

M M Brentani, C R Carvalho, P H Saldiva, M M Pacheco, C T Oshima.   

Abstract

As an initial step in investigating the role of steroid hormones in lymphangiomyomatosis, the cytosolic receptors for steroid hormones were determined by a dextran charcoal method. Specific saturable receptors were found for estrogens (measured with [3H] estradiol +/- unlabeled diethylstilbestrol), progestins (measured with [3H] R5020 +/- unlabeled R5020), and glucocorticoids (measured with [3H] dexamethasone +/- unlabeled dexamethasone); they were absent for androgens (measured with [3H] R1881 +/- unlabeled R1881). Even though receptor levels were of low absolute value, they were significant because specimens of normal lung display no receptor at all. Steroid hormones may have direct effects on pulmonary lymphangiomyomatosis tissue mediated by specific receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690259     DOI: 10.1378/chest.85.1.96

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.

Authors:  Yang Sun; Erik Zhang; Taotao Lao; Ana M Pereira; Chenggang Li; Li Xiong; Tasha Morrison; Kathleen J Haley; Xiaobo Zhou; Jane J Yu
Journal:  Horm Cancer       Date:  2014-07-29       Impact factor: 3.869

3.  Lymphangiomyomatosis: a respiratory illness with an endocrinologic therapy.

Authors:  H O Sieker; K S McCarty
Journal:  Trans Am Clin Climatol Assoc       Date:  1988

4.  Pulmonary tuberous sclerosis treated with tamoxifen and progesterone.

Authors:  C J Westermann; A C Oostveen; S S Wagenaar; C Hilvering; S E Overbeek; D Verheijen-Breemhaar; B Corrin
Journal:  Thorax       Date:  1986-11       Impact factor: 9.139

5.  Lymphangioleiomyomatosis presenting in a postmenopausal woman.

Authors:  W Sinclair; J L Wright; A Churg
Journal:  Thorax       Date:  1985-06       Impact factor: 9.139

Review 6.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

7.  mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.

Authors:  Jane Yu; Elizabeth Petri Henske
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

8.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

Review 9.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

10.  Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study.

Authors:  I Wahedna; S Cooper; J Williams; I C Paterson; J R Britton; A E Tattersfield
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.